✉news HealthMedicine first seen 3 h ago, last 17 min ago, peak #22

Retatrutide Shows Record Weight Loss in Type 2 Diabetes

Original: Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes

The triple agonist drug retatrutide has delivered unprecedented weight loss results in people with type 2 diabetes, according to new findings reported by Inside Precision Medicine. The therapy, which targets three metabolic receptors, is being watched closely as trial data suggest it could outperform existing obesity and diabetes medications such as tirzepatide and semaglutide.

Why now: New trial results suggest retatrutide may set a new benchmark for weight loss treatment in type 2 diabetes.

retatrutideEli Lillytype 2 diabetesobesity

Open on news →

Rank over time, top of the chart is #1. 3 snapshots from 3 h ago to 17 min ago.

Evidence

• Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes · Inside Precision Medicine

API: https://socialmediatrends-api.osmike.com/v1/trends/443777